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Background 
Vascular endothelial growth factor-A (VEGF) is produced by most cancer cells as multiple 
alternatively spliced isoforms, which display distinct receptor and matrix binding characteristics. In 
addition to being a major inducer of tumour angiogenesis, VEGF also has complex functions in 
angiogenesis-independent aspects of tumour growth,but the role of individual VEGF isoforms remains 
poorly understood. Here we investigated the effects of endogenous VEGF isoform expression on 
tumour cell migration and invasion. 
Method 
We used a panel of mouse fibrosarcoma cells we developed (fs188, fs164 and fs120) that express single 
VEGF isoforms (188, 164 or 120 respectively), under endogenous promoter control. We investigated 
adhesion to different matrices, 2D migration and invasion through 3D collagen. 
Results 
Fs188 cells, are typically mesenchymal, form ruffles, display strong integrin-dependent adhesion and 
express high levels of pERK1/2 and pAKT. In contrast, fs164 and fs120 cells are not typically 
mesenchymal in morphology; they display weak binding to collagen, lack ruffles and align 
longitudinally forming long multicellular chains and abundant cell-cell contacts. On 3D collagen, fs188 
cells remain mesenchymal while fs164 and fs120 cells adopt a rounded/amoeboid and a mix of 
rounded/mesenchymal morphologies respectively. Cell morphology and migration are dependent on 
the cytoskeleton and actinomyosin contractility, to provide traction force in mesenchymal movement, 
and cortical contraction for rounded amoeboid motility. Consistent with their mesenchymal 
characteristics, fs188 cells migrated faster in 2D and invaded 3D collagen more efficiently than fs164 or 
fs120 cells. Contractility inhibitors caused fs164/fs120 cells to switch to a mesenchymal morphology and 
accelerated their migration but not that of fs188 cells. 
Conclusion 
VEGF isoforms are emerging as potential biomarkers for anti-VEGF therapies. Our results suggest that 
individual VEGF isoforms influence the migration and invasion strategies of tumour cells thus adding 
to the complexity of VEGF signaling within the tumor microenvironment. 
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